Journal ArticleDOI
Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases.
Reads0
Chats0
TLDR
It is suggested that rituximab may be effective for induction of remission in selected EGPA patients and warrant further studies to evaluate safety and efficacy.About:
This article is published in Joint Bone Spine.The article was published on 2016-01-01. It has received 22 citations till now. The article focuses on the topics: Rituximab & Granulomatosis with polyangiitis.read more
Citations
More filters
Journal ArticleDOI
Immunotherapy in Eosinophilic Granulomatosis with Polyangiitis: A New Step Forward?
TL;DR: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has distinct features, namely asthma, common rhino-sinusal involvement, hypereosinophilia, tissue infiltration with eOSinophils and necrotizing granulomatosis Vasculitis.
Journal ArticleDOI
Eficacia y seguridad de rituximab en neuropatía vasculítica: revisión sistemática
Natalia Mena-Vázquez,Pablo Cabezudo-García,Clara Fuego Varela,Sara Manrique-Arija,Antonio Fernández-Nebro +4 more
TL;DR: Rituximab seems an effective and safe treatment for VN in the context of cryoglobulinemic vasculitis is lacking, and evidence for specific efficacy in VN on the basis of other types of vasculitic neuropathy is lacking.
Journal ArticleDOI
Efficacy and safety of Rituximab in vasculitic neuropathy: a systematic review of the literature
Natalia Mena-Vázquez,Pablo Cabezudo-García,Clara Fuego Varela,Sara Manrique-Arija,Antonio Fernández-Nebro +4 more
TL;DR: Rituximab seems an effective and safe treatment for VN in the context of cryoglobulinemic vasculitis, and evidence for specific efficacy in VN on the basis of other types of vasculitic neuropathy is lacking.
Journal ArticleDOI
Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis.
TL;DR: The clinical utility of eotaxin-3 as a possible biomarker of EGPA relapse is investigated in 38 patients with EGPA, with a total of 38 patients at a mean age of 38.
Book ChapterDOI
Autoimmune and Autoantibody-Associated Encephalomyelopathies
TL;DR: The particular focus of this chapter is on autoimmune disorders associated with encephalitis or myelitis, subdivided into two groups: systemic diseases with CNS manifestations and (2) Ab-associated disorders of the CNS.
References
More filters
Journal ArticleDOI
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
TL;DR: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Watts; Arthritis & Rheumatism
2012 Revised International Chapel Hill Consensus Conference Nomenclature of
John Charles Jennette,Ronald Falk,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Peter Lamprecht,Raashid Luqmani,Seza Ozen,Andrew J. Rees,Scott Dgi,Ulrich Specks,Kei Takahashi,Richard A. Watts +16 more
TL;DR: In this article, the running head is assigned to one of the following candidates:Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Ferrardo F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees
Journal ArticleDOI
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
Journal ArticleDOI
The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)
Alfonse T. Masi,Alfonse T. Masi,Gene G. Hunder,Gene G. Hunder,J. T. Lie,J. T. Lie,Beat A. Michel,Daniel A. Bloch,Daniel A. Bloch,William P. Arend,William P. Arend,Leonard H. Calabrese,Leonard H. Calabrese,Steven M. Edworthy,Steven M. Edworthy,Anthony S. Fauci,Anthony S. Fauci,Randi Y. Leavitt,Randi Y. Leavitt,Robert W. Lightfoot,Robert W. Lightfoot,Dennis J. McShane,Dennis J. McShane,John A. Mills,John A. Mills,Mary Betty Stevens,Mary Betty Stevens,Stanley L. Wallace,Nathan J. Zvaifler,Nathan J. Zvaifler +29 more
TL;DR: Criteria for the classification of Churg-Strauss syndrome were developed by comparing 20 patients who had this diagnosis with 787 control patients with other forms of vasculitis, and advantages of the traditional format compared with the classification tree format are discussed.
Journal ArticleDOI
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel B Jones,Jan Willem Cohen Tervaert,Thomas H. Hauser,Raashid Luqmani,Matthew D. Morgan,Chen Au Peh,Caroline O. S. Savage,Mårten Segelmark,Vladimir Tesar,Pieter van Paassen,D Walsh,Michael Walsh,Kerstin Westman,David Jayne +13 more
TL;DR: A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis and was not associated with reductions in early severe adverse events.
Related Papers (5)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loïc Guillevin,Christian Pagnoux,Alexandre Karras,Chahéra Khouatra,Olivier Aumaître,Pascal Cohen,François Maurier,Olivier Decaux,Jacques Ninet,P. Gobert,Thomas Quemeneur,Claire Blanchard-Delaunay,Pascal Godmer,Xavier Puéchal,Pierre-Louis Carron,Pierre-Yves Hatron,Nicolas Limal,Mohamed Hamidou,Maize Ducret,Eric Daugas,Thomas Papo,Bernard Bonnotte,Alfred Mahr,Philippe Ravaud,Luc Mouthon +24 more
Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
Cloé Comarmond,Christian Pagnoux,Mehdi Khellaf,Jean-François Cordier,Mohamed Hamidou,Jean-François Viallard,François Maurier,Stéphane Jouneau,Boris Bienvenu,Xavier Puéchal,Olivier Aumaître,Guillaume Le Guenno,Alain Le Quellec,Ramiro Cevallos,Olivier Fain,Bertrand Godeau,Raphaèle Seror,Bertrand Dunogué,Alfred Mahr,Philippe Guilpain,Pascal Cohen,Achille Aouba,Luc Mouthon,Loïc Guillevin +23 more